Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 21-30 of 34 for

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

    Rochester, MN

  2. Global Trial in APG2575 for Patients With CLL/​SLL

    Jacksonville, FL

  3. Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/​Refractory T-cell Non-Hodgkin Lymphoma

    Scottsdale/Phoenix, AZ

  4. Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus RCHOP in Participants with Previously Untreated High-risk Large B-cell Lymphoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma

    Scottsdale/Phoenix, AZ, Rochester, MN, Albert Lea, MN, Eau Claire, WI, La Crosse, WI, Mankato, MN

  6. Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

    Jacksonville, FL, Rochester, MN

  7. Inotuzumab Ozogamicin And Post-Induction Chemotherapy In Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, And B-LLy

    Rochester, MN

  8. Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

    Rochester, MN, Rochester, MN

  9. AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) B-cell NHL

    Rochester, MN

  10. Reduced Dose Hypofractionated Radiotherapy For Indolent Non-hodgkin Lymphoma

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ, Albert Lea, MN, Eau Claire, WI, La Crosse, WI, Mankato, MN

.

Mayo Clinic Footer